Melanotan 1 (MT1), also known as afamelanotide, is a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH). It mimics the body’s natural hormone that regulates melanin production, leading to skin tanning without UV exposure. Developed in the 1980s at the University of Arizona, it’s primarily researched for medical uses but is also popular in bodybuilding and tanning communities.

Medical Uses and Approval

• Approved Indication: Afamelanotide (brand name Scenesse) is FDA-approved (since 2019 in the US, earlier in Europe) for preventing phototoxicity in adult patients with erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe pain from sunlight exposure. It’s administered as a subcutaneous implant every 2 months.
• Mechanism: Binds to melanocortin-1 receptors (MC1R) on melanocytes, increasing eumelanin (dark pigment) production for UV protection.
• Evidence: Clinical trials (e.g., Phase 3 studies in NEJM 2014) showed it reduced pain episodes by 50-75% in EPP patients, with good tolerability.

Non-Medical Uses (Tanning)

• Often used off-label for cosmetic tanning: Injections or nasal sprays promote deep, even tans in fair-skinned people, potentially reducing sunburn risk.
• Comparison to Melanotan 2: MT1 is more selective for skin pigmentation (fewer side effects like nausea or libido changes), while MT2 affects appetite and erections too.

Dosage and Administration (Research Contexts)

• Typical Research/Off-Label: 0.25-1 mg subcutaneous injections daily or every other day for 1-2 weeks, then maintenance (e.g., 0.5 mg/week). Start low to assess tolerance.
• Nasal Version: Less effective (10-20% bioavailability vs. 80% injections).
• Evidence: User reports and small studies (e.g., J. Invest. Dermatol. 1996) confirm tanning at 0.25 mg/day, but no large RCTs for cosmetics.

Side Effects and Risks

• Common: Nausea, facial flushing, increased moles/freckles, appetite suppression.
• Serious: Potential skin cancer risk (melanin stimulation may promote melanoma in predisposed individuals—animal studies show mixed results). Long-term data limited.
• Other: Darkening of gums, nausea (less than MT2), priapism (rare).
• Evidence: Post-marketing surveillance of Scenesse shows low adverse events (e.g., <5% serious), but unregulated versions may contain impurities.

Legality and Availability

• Prescription-Only: Legal as Scenesse for EPP (costs ~$30,000/year in US).
• Gray Market: Unregulated peptides sold online (e.g., from China) are not FDA-approved for tanning, illegal to market/sell for human use in many countries (US, UK, Australia). Purity varies (often <80% pure per lab tests).
• Bans: Australia/UK classify research peptides as Schedule 4 poisons; possession for personal use often overlooked but risky.

Safety and Recommendations

• Not Recommended for General Use: Lacks long-term safety data for healthy people. Consult a doctor; get baseline skin checks.
• Alternatives: Self-tanners (DHA-based), sunless sprays, or UV exposure with sunscreen.
• Research Backing: Peer-reviewed sources include PubMed (e.g., PMID 24685649 for efficacy) and FDA label. Avoid if history of melanoma or kidney issues.

For personalized advice, see a healthcare provider. Sources: FDA.gov, PubMed, Clinuvel (manufacturer).